Investors
Partnering with Pioneering Organisations
Transforming Inflammatory Disease Treatment
At EVolution Therapeutics, we have a clear vision: to transform the treatment of inflammatory diseases through advanced nanoparticle-based therapeutics.
We engineer targeted nanoparticle delivery systems designed to modulate the innate immune response. Our research demonstrates the ability to harness specific bioactive molecules and deliver them directly to sites of inflammation, enabling precise, mechanism-driven intervention.
Our ambition is to drive a true paradigm shift — moving beyond passive symptom management toward active resolution and immune reprogramming. By restoring immune balance and supporting tissue repair, we aim to redefine treatment across multiple inflammatory indications.
We are now advancing our platform toward the clinic. Our focus is to progress lead programmes through preclinical development, generate robust translational data, and prepare for first-in-human clinical trials through strong efficacy, delivery optimisation, and regulatory planning.
Through open innovation and strategic collaboration, we aim to maximise the impact of our platform and deliver meaningful therapies to patients with significant unmet medical needs.
We are currently raising pre-seed investment to accelerate platform development, expand our translational programme, and progress our lead therapeutic candidates toward clinical trials. We welcome conversations with investors who share our belief in next-generation, mechanism-led therapeutics and scalable platform-based innovation.
Join us in shaping the next generation of inflammatory disease treatment — advancing therapies designed not just to manage disease, but to actively restore immune balance, enable clinical translation, and deliver lasting patient impact.
Our Potential
A revolutionary nanoparticle-based therapy designed to actively accelerate healing by targeting the biological drivers of inflammation — moving beyond treatments that rely on passive management and toward true disease resolution.
Market Opportunity
In the US alone, non-healing wounds impact the quality of life of approximately 2.5% of the total population, at a cost of $28 Billion annually.